Heat shock protein–based therapy as a potential candidate for treating the sphingolipidoses

A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES

Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases

Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351

Induction of the Vitamin D Receptor Attenuates Autophagy Dysfunction-Mediated Cell Death Following Traumatic Brain Injury

Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, R. C., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,214

Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data

Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,565

The role of autophagy in neurodegenerative disease

Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059

Niemann-Pick disease type C

Vanier, M. T. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-16 · Cited by 1,222

The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions

Daugaard, M., Rohde, M., & Jäättelä, M. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.05.039 · Cited by 1,177

Modulation of neurodegeneration by molecular chaperones

Muchowski, P. J., & Wacker, J. L. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1587 · Cited by 1,043

A Cross-Sectional Study

Drozdzowska, B., Pluskiewicz, W., Halaba, Z. P., Misiołek, H., & Beck, B. R. (2005) · Cited by 984

CD91 Is a Common Receptor for Heat Shock Proteins gp96, hsp90, hsp70, and Calreticulin

Basu, S., Binder, R. J., Ramalingam, T., & Srivastava, P. K. (2001) · Immunity · doi:10.1016/s1074-7613(01)00111-x · Cited by 900

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680

Lysosomal storage diseases

Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052

LYSOSOMAL STORAGE DISEASES

Neufeld, E. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001353 · Cited by 924

Lysosomal membrane permeabilization and cell death

Wang, F., Gómez‐Sintes, R., & Boya, P. (2018) · Traffic · doi:10.1111/tra.12613 · Cited by 804

Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG

Gu, Y., Liu, Y., Fu, L., Zhai, L., Zhu, J., Han, Y., Jiang, Y., Zhang, Y., Zhang, P., Jiang, Z., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0309-y · Cited by 264

Emptying the stores: lysosomal diseases and therapeutic strategies

Platt, F. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.214 · Cited by 257

The rapidly evolving view of lysosomal storage diseases

Parenti, G., Medina, D. L., & Ballabio, A. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012836 · Cited by 230

Amyloid assembly and disassembly

Chuang, E., Hori, A. M., Hesketh, C. D., & Shorter, J. (2018) · Journal of Cell Science · doi:10.1242/jcs.189928 · Cited by 188

Biophysical and Mechanistic Models for Disease-Causing Protein Variants

Stein, A., Fowler, D. M., Hartmann‐Petersen, R., & Lindorff‐Larsen, K. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.01.003 · Cited by 167

Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives

Solomon, M. A., & Muro, S. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.004 · Cited by 164

Genetics and Therapies for GM2 Gangliosidosis

Cachón-González, M. B., Zaccariotto, E., & Cox, T. M. (2018) · Current Gene Therapy · doi:10.2174/1566523218666180404162622 · Cited by 141

Treatment strategies for lysosomal storage disorders

Beck, M. (2017) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.13600 · Cited by 114

Hsp70 interactions with membrane lipids regulate cellular functions in health and disease

Balogi, Z., Multhoff, G., Jensen, T. K., Lloyd‐Evans, E., Yamashima, T., Jäättelä, M., Harwood, J. L., & Vı́gh, L. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.01.004 · Cited by 117

Heat Shock Proteins and Autophagy Pathways in Neuroprotection: From Molecular Bases to Pharmacological Interventions

Penke, B., Bogár, F., Crul, T., Sántha, M., Tóth, M. E., & Vı́gh, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010325 · Cited by 112

Niemann–Pick type C disease: cellular pathology and pharmacotherapy

Wheeler, S., & Sillence, D. J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14895 · Cited by 111

Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment

Mengel, K. E., Patterson, M. C., Riol, R. M. D., del Toro, M., Deodato, F., Gautschi, M., Grünewald, S., Grønborg, S. W., Harmatz, P., Héron, B., et al. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12428 · Cited by 100

Navigating the landscape of protein folding and proteostasis: from molecular chaperones to therapeutic innovations

Kuzu, O. F., Granerud, L. J. T., & Saatcioglu, F. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02439-w · Cited by 128

Membrane-lipid therapy: A historical perspective of membrane-targeted therapies — From lipid bilayer structure to the pathophysiological regulation of cells

Escribá, P. V. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.05.017 · Cited by 98

Inclusion Body Myositis: Update on Pathogenesis and Treatment

Naddaf, E., Barohn, R. J., & Dimachkie, M. M. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0658-8 · Cited by 89

Acetyl-leucine slows disease progression in lysosomal storage disorders

Kaya, E., Smith, D. A., Smith, C., Morris, L., Brémovà-Ertl, T., Cortina‐Borja, M., Fineran, P., Morten, K., Poulton, J., Boland, B., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa148 · Cited by 86

A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology

Birket, M. J., Raibaud, S., Lettieri, M., Adamson, A. D., Letang, V., Cervello, P., Redon, N., Ret, G., Viale, S., Wang, B., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.07.004 · Cited by 77

Role of a Heat Shock Transcription Factor and the Major Heat Shock Protein Hsp70 in Memory Formation and Neuroprotection

Zatsepina, O. G., Evgen’ev, M. B., & Garbuz, D. G. (2021) · Cells · doi:10.3390/cells10071638 · Cited by 80

Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials

Cortina‐Borja, M., Vruchte, D. T., Mengel, E., Amraoui, Y., Imrie, J., Jones, S. A., Dali, C. Í., Fineran, P., Kirkegaard, T., Runz, H., et al. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0880-9 · Cited by 72

NPC1 enables cholesterol mobilization during long‐term potentiation that can be restored in Niemann–Pick disease type C by CYP46A1 activation

Mitroi, D. N., Pereyra, G., Soto‐Huelin, B., Senovilla, F., Kobayashi, T., Esteban, J. A., & Ledesma, M. D. (2019) · EMBO Reports · doi:10.15252/embr.201948143 · Cited by 69

Graphene oxide / BaHoF5 / PEG nanocomposite for dual-modal imaging and heat shock protein inhibitor-sensitized tumor photothermal therapy

Xu, C., Zhang, M., Wang, C., Zhang, J., Wu, H., & Yang, S. (2019) · Carbon · doi:10.1016/j.carbon.2019.10.105 · Cited by 69

Understanding the phenotypic variability in Niemann-Pick disease type C (NPC): a need for precision medicine

Heras, M. L., Szenfeld, B., Ballout, R. A., Buratti, E., Zanlungo, S., Dardis, A., & Klein, A. D. (2023) · npj Genomic Medicine · doi:10.1038/s41525-023-00365-w · Cited by 69

Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease

Horowitz, M., Braunstein, H., Zimran, A., Revel‐Vilk, S., & Göker-Alpan, Ö. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114402 · Cited by 67

Insight into the Role of Extracellular Vesicles in Lysosomal Storage Disorders

Tancini, B., Buratta, S., Sagini, K., Costanzi, E., Delo, F., Urbanelli, L., & Emiliani, C. (2019) · Genes · doi:10.3390/genes10070510 · Cited by 59

The interaction of heat shock proteins with cellular membranes: a historical perspective

Maio, A. D., & Hightower, L. E. (2021) · Cell Stress and Chaperones · doi:10.1007/s12192-021-01228-y · Cited by 53

Gaucher disease – more than just a rare lipid storage disease

Roh, J., Subramanian, S., Weinreb, N. J., & Kartha, R. V. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02174-z · Cited by 59

The Niemann-Pick type diseases – A synopsis of inborn errors in sphingolipid and cholesterol metabolism

Pfrieger, F. W. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101225 · Cited by 54

Evaluation of age of death in Niemann-Pick disease, type C: Utility of disease support group websites to understand natural history

Bianconi, S. E., Hammond, D., Farhat, N. Y., Do, A. N. D., Jenkins, K., Cougnoux, A., Martin, K. B., & Porter, F. D. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.02.004 · Cited by 51

The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase

Fog, C. K., Zago, P., Malini, E., Solanko, L. M., Peruzzo, P., Bornæs, C., Magnoni, R., Mehmedbašić, A., Petersen, N. H. T., Bembi, B., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.037 · Cited by 50

Clinical and Molecular Features of Early Infantile Niemann Pick Type C Disease

Yılmaz, B. Ş., Baruteau, J., Rahim, A. A., & Gissen, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145059 · Cited by 48

Protein stability and degradation in health and disease

Clausen, L., Abildgaard, A. B., Gersing, S. K., Stein, A., Lindorff‐Larsen, K., & Hartmann‐Petersen, R. (2018) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2018.09.002 · Cited by 56

Molecular Mechanisms Underlying Neuroprotective Effect of Intranasal Administration of Human Hsp70 in Mouse Model of Alzheimer’s Disease

Evgen’ev, M. B., Krasnov, G. S., Nesterova, I. V., Garbuz, D. G., Карпов, В. Л., Morozov, A. V., Snezhkina, A. V., Samokhin, A. N., Sergeev, A., Куликов, А. М., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170398 · Cited by 45

Drug‐induced increase in lysobisphosphatidic acid reduces the cholesterol overload in Niemann–Pick type C cells and mice

Moreau, D., Vacca, F., Vossio, S., Scott, C. C., Colaço, A., Montoya, J. P., Ferguson, C., Daμμe, M., Moniatte, M., Parton, R. G., et al. (2019) · EMBO Reports · doi:10.15252/embr.201847055 · Cited by 44

Targeting Cancer Lysosomes with Good Old Cationic Amphiphilic Drugs

Ellegaard, A., Bach, P. B., & Jäättelä, M. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_56 · Cited by 44

Closest horizons of Hsp70 engagement to manage neurodegeneration

Venediktov, A. A., Bushueva, O. Y., Kudryavtseva, V. A., Kuzmin, E. A., Moiseeva, A. V., Baldycheva, A. V., Meglinski, I. V., & Piavchenko, G. A. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1230436 · Cited by 44

Osteoarthritis: molecular pathogenesis and potential therapeutic options

Zhang, Y., Han, Y., Sun, Y., Hao, L., Gao, Y., Ye, J., Wang, H., Zhang, T., Liu, Y., & Yang, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02556-6 · Cited by 48

Control of mitosis, inflammation, and cell motility by limited leakage of lysosomes

Stahl-Meyer, J., Stahl-Meyer, K., & Jäättelä, M. (2021) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2021.02.003 · Cited by 40

The CD22-IGF2R interaction is a therapeutic target for microglial lysosome dysfunction in Niemann-Pick type C

Pluvinage, J. V., Sun, J., Claes, C., Flynn, R. A., Haney, M. S., Iram, T., Meng, X., Lindemann, R. C., Riley, N. M., Danhash, E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg2919 · Cited by 40

Fabry disease: Mechanism and therapeutics strategies

Li, X., Ren, X., Zhang, Y., Ding, L., Huo, M., & Li, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1025740 · Cited by 45

Niemann-Pick Disease, Type C: Diagnosis, Management and Disease-Targeted Therapies in Development

Berry‐Kravis, E. (2021) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2021.100879 · Cited by 39

Brain-wide microglia replacement using a nonconditioning strategy ameliorates pathology in mouse models of neurological disorders

Chen, D., Wang, C., Chen, X., Li, J., Chen, S., Li, Y., Ma, F., Li, T., Zou, M., Li, X., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ads6111 · Cited by 42

Inherited disorders of lysosomal membrane transporters

Huizing, M., & Gahl, W. A. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183336 · Cited by 41

Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial

Machado, P., McDermott, M., Blaettler, T., Sundgreen, C., Amato, A. A., Ciafaloni, E., Freimer, M. L., Gibson, S. B., Jones, S. M., Levine, T., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00275-2 · Cited by 38

Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder

Kulkarni, A., Caporali, P., Dolas, A., Johny, S., Goyal, S., Dragotto, J., Macone, A., Jayaraman, R., & Fiorenza, M. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-27926-9 · Cited by 37

Stroke Recovery in Rats after 24‐Hour–Delayed Intramuscular Neurotrophin‐3 Infusion

Duricki, D. A., Drndarski, S., Bernanos, M., Wood, T., Bosch, K. D., Chen, Q., Shine, H. D., Simmons, C., Williams, S., McMahon, S. B., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25386 · Cited by 37

Animal models for Niemann-Pick type C: implications for drug discovery & development

Fog, C. K., & Kirkegaard, T. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1588882 · Cited by 36

Understanding and Treating Niemann–Pick Type C Disease: Models Matter

Pallottini, V., & Pfrieger, F. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238979 · Cited by 40

High-content screen for modifiers of Niemann-Pick type C disease in patient cells

Pugach, E. K., Feltes, M., Kaufman, R. J., Ory, D. S., & Bang, A. G. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy117 · Cited by 33

Genetic background modifies phenotypic severity and longevity in a mouse model of Niemann-Pick disease type C1

Rodriguez‐Gil, J. L., Watkins‐Chow, D. E., Baxter, L. L., Elliot, G., Harper, U. L., Wincovitch, S., Wedel, J. C., Incao, A. A., Huebecker, M., Boehm, F. J., et al. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.042614 · Cited by 33

The Effect of Human HSP70 Administration on a Mouse Model of Alzheimer’s Disease Strongly Depends on Transgenicity and Age

Evgen’ev, M. B., Bobkova, N. V., Krasnov, G. S., Garbuz, D. G., Funikov, S. Y., Kudryavtseva, A. V., Куликов, А. М., Samokhin, A. N., Maltsev, A. V., & Nesterova, I. V. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180987 · Cited by 33

Induced pluripotent stem cell models of lysosomal storage disorders

Borger, D. K., McMahon, B., Lal, T. R., Serra‐Vinardell, J., Aflaki, E., & Sidransky, E. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.029009 · Cited by 34

Finding pathogenic commonalities between Niemann-Pick type C and other lysosomal storage disorders: Opportunities for shared therapeutic interventions

Yañez, M. J., Marín, T., Balboa, E., Klein, A. D., Alvarez, A. R., & Zanlungo, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165875 · Cited by 30

Niemann-Pick disease, type C and Roscoe Brady

Patterson, M. C., & Walkley, S. U. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.11.008 · Cited by 28

Addressing neurodegeneration in lysosomal storage disorders: Advances in Niemann Pick diseases

Toledano‐Zaragoza, A., & Ledesma, M. D. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107851 · Cited by 28

Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study

Mengel, K. E., Bembi, B., del Toro, M., Deodato, F., Gautschi, M., Grünewald, S., Grønborg, S. W., Héron, B., Maier, E. M., Roubertie, A., et al. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01616-0 · Cited by 31

4-HNE induces proinflammatory cytokines of human retinal pigment epithelial cells by promoting extracellular efflux of HSP70

Yang, H., Hu, R., Sun, H., Chen, B., Li, X., & Chen, J.-B. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107792 · Cited by 27

Developments in evidence creation for treatments of inborn errors of metabolism

Stöckler‐Ipsiroglu, S., Potter, B. K., Yuskiv, N., Tingley, K., Patterson, M. C., & van Karnebeek, C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12315 · Cited by 28

Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1

Campbell, K. S., Cawley, N. X., Luke, R., Scott, K. E. J., Johnson, N., Farhat, N. Y., Alexander, D. M., Wassif, C. A., Li, W., Cologna, S. M., et al. (2023) · Biomarker Research · doi:10.1186/s40364-023-00448-x · Cited by 26

Individualized management of genetic diversity in Niemann-Pick C1 through modulation of the Hsp70 chaperone system

Wang, C., Scott, S. M., Sun, S., Zhao, P., Hutt, D. M., Shao, H., Gestwicki, J. E., & Balch, W. E. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz215 · Cited by 26

Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases

Favret, J., Weinstock, N. I., Feltri, M. L., & Shin, D. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00057 · Cited by 28

Myelin Defects in Niemann–Pick Type C Disease: Mechanisms and Possible Therapeutic Perspectives

Bernardo, A., Nuccio, C. D., Visentin, S., Martire, A., Minghetti, L., Popoli, P., & Ferrante, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168858 · Cited by 27

2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease

Davidson, J. W., Molitor, E. A., Moores, S., Gale, S. E., Subramanian, K., Jiang, X., Sidhu, R., Kell, P. J., Zhang, J., Fujiwara, H., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.04.011 · Cited by 26

Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease

Seemann, S., Ernst, M., Cimmaruta, C., Struckmann, S., Cozma, C., Koczan, D., Knospe, A., Haake, L. R., Citro, V., Bräuer, A. U., et al. (2020) · Biochemical Journal · doi:10.1042/bcj20190513 · Cited by 24

Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann-Pick Disease Type C Using Crosslinked 2-Hydroxypropyl-β-cyclodextrin.

Carradori, D., Chen, H., Werner, B., Shah, A., Leonardi, C., Usuelli, M., Mezzenga, R., Platt, F., & Leroux, J. (2020) · Small · doi:10.1002/smll.202004735 · Cited by 19

Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones

Monticelli, M., Liguori, L., Allocca, M., Bosso, A., Andreotti, G., Lukáš, J., Monti, M. C., Morretta, E., Cubellis, M. V., & Mele, B. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095105 · Cited by 25

Transcriptome of HPβCD-treated Niemann-Pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics

Rodriguez‐Gil, J. L., Baxter, L. L., Watkins‐Chow, D. E., Johnson, N. L., Davidson, C. D., Carlson, S. R., Incao, A. A., Program, N. C. S., Wallom, K., Farhat, N. Y., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab194 · Cited by 22

Amplifying the Heat Shock Response Ameliorates ALS and FTD Pathology in Mouse and Human Models

Ahmed, M., Spicer, C., Harley, J., Petersen, N., Taylor, J. P., Kirkegaard, T., Hanna, M. G., Patani, R., & Greensmith, L. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03509-2 · Cited by 21

Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC

Benussi, A., Cotelli, M. S., Padovani, A., & Borroni, B. (2018) · F1000Research · doi:10.12688/f1000research.12361.1 · Cited by 20

NPC1 Deficiency in Mice is Associated with Fetal Growth Restriction, Neonatal Lethality and Abnormal Lung Pathology

Rodriguez‐Gil, J. L., Watkins‐Chow, D. E., Baxter, L. L., Yokoyama, T., Zerfas, P. M., Starost, M. F., Gahl, W. A., Malicdan, M. C. V., Porter, F. D., Platt, F. M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010012 · Cited by 21

4-HNE Induces Apoptosis of Human Retinal Pigment Epithelial Cells by Modifying HSP70

Yang, L., Chen, H., Wang, J., Xia, T., Sun, H., Yuan, C., Liu, S., & Chen, J.-B. (2019) · Current Medical Science · doi:10.1007/s11596-019-2057-8 · Cited by 21

Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid

Subramanian, K., Hutt, D. M., Scott, S. M., Gupta, V. R., Mao, S., & Balch, W. E. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010524 · Cited by 21

PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases

Zhao, X., Lin, Y., Liou, B., Fu, W., Jian, J., Fannin, V., Zhang, W., Setchell, K. D. R., Grabowski, G. A., Sun, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210442120 · Cited by 22

The Role of Hsp70 in Adaptation to Adverse Conditions and Its Possible Medical Application

Evgen’ev, M. B., Onikienko, S. B., Chuvakova, L. N., Garbuz, D. G., & Zatsepina, O. G. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2802025 · Cited by 19

Niemann-Pick Disease Type C (NPDC) by Mutation of NPC1 and NPC2: Aberrant Lysosomal Cholesterol Trafficking and Oxidative Stress

Lee, D., & Hong, J. H. (2023) · Antioxidants · doi:10.3390/antiox12122021 · Cited by 19

Mutation-induced LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndrome

Busley, A. V., Gutiérrez‐Gutiérrez, Ó., Hammer, E., Koitka, F., Mirzaiebadizi, A., Steinegger, M., Pape, C., Böhmer, L., Schroeder, H., Kleinsorge, M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114448 · Cited by 19

Accumulation of alkyl-lysophosphatidylcholines in Niemann-Pick disease type C1

Mishra, S., Kell, P. J., Scherrer, D. E., Dietzen, D. J., Vite, C. H., Berry‐Kravis, E., Davidson, C. D., Cologna, S. M., Porter, F. D., Ory, D. S., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100600 · Cited by 18

HSP70 induces liver X receptor pathway activation and cholesterol reduction in vitro and in vivo

Güngör, B., Vanharanta, L., Hölttä‐Vuori, M., Pirhonen, J., Petersen, N. H. T., Gramolelli, S., Ojala, P. M., Kirkegaard, T., & Ikonen, E. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.07.005 · Cited by 19

Recent Advances and Novel Treatments for Sphingolipidoses

Arenz, C. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0065 · Cited by 18

HSP90 inhibitors reduce cholesterol storage in Niemann-Pick type C1 mutant fibroblasts

Pipalia, N. H., Saad, S. Z., Subramanian, K., Cross, A. C., al-Motawa, A., Garg, K., Blagg, B. S. J., Neckers, L., Helquist, P. M., Wiest, O., et al. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100114 · Cited by 17

Current advancements in therapy for Niemann-Pick disease: progress and pitfalls

Brémovà-Ertl, T., & Schneider, S. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2215386 · Cited by 16

mRNA Treatment Rescues Niemann–Pick Disease Type C1 in Patient Fibroblasts

Furtado, D. L., Cortez‐Jugo, C., Hung, Y. H., Bush, A. I., & Caruso, F. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00463 · Cited by 16

Cleavage of Hsp70.1 causes lysosomal cell death under stress conditions

Yamashima, T., Mochly‐Rosen, D., Wakatsuki, S., Mizukoshi, E., Seike, T., Larus, I., Chen, C., Takemura, M., Saitō, H., & Ohashi, A. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1378656 · Cited by 15

Identification of proteotoxic and proteoprotective bacteria that non-specifically affect proteins associated with neurodegenerative diseases

Walker, A. C., Bhargava, R., Bucher, M. J., Argote, Y. M., Brust, A. S., & Czyż, D. M. (2024) · iScience · doi:10.1016/j.isci.2024.110828 · Cited by 15

Protecting Encapsulin Nanoparticles with Cysteine-Knot Miniproteins

Klem, R., de Ruiter, M. V., & Cornelissen, J. J. L. M. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00630 · Cited by 15

Conformational dynamics of free and membrane-bound human Hsp70 in model cytosolic and endo-lysosomal environments

Calvaresi, V., Truelsen, L. T., Larsen, S. B., Petersen, N. H. T., Kirkegaard, T., & Rand, K. D. (2021) · Communications Biology · doi:10.1038/s42003-021-02892-7 · Cited by 14

The expanding boundaries of sphingolipid lysosomal storage diseases; insights from Niemann–Pick disease type C

Platt, F. M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220711 · Cited by 14

Arimoclomol: First Approval

Keam, S. J. (2024) · Drugs · doi:10.1007/s40265-024-02129-x · Cited by 14

A cross‐sectional, prospective ocular motor study in 72 patients with Niemann‐Pick disease type C

Brémovà-Ertl, T., Abel, L. A., Walterfang, M., Salsano, E., Ardissone, A., Malinová, V., Kolníková, M., Bayarri, J. G., Tavasoli, A. R., Ashrafi, M. R., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14955 · Cited by 14

Ellagic acid and its metabolites urolithins A/B ameliorate most common disease phenotypes in cellular and mouse models for lysosomal storage disorders by enhancing extracellular vesicle secretion

Soto‐Huelin, B., Babiy, B., Pastor, Ó., Díaz-García, M., Toledano‐Zaragoza, A., Frutos, M. D., Espı́n, J. C., Tomás-Barberán, F. A., Busto, R., & Ledesma, M. D. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106141 · Cited by 14

Correlation of age of onset and clinical severity in Niemann–Pick disease type C1 with lysosomal abnormalities and gene expression

Baxter, L. L., Watkins‐Chow, D. E., Johnson, N. L., Farhat, N. Y., Platt, F. M., Dale, R., Porter, F. D., Pavan, W. J., & Rodriguez‐Gil, J. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-06112-y · Cited by 13

Heat shock protein amplification improves cerebellar myelination in the Npc1nih mouse model

Gray, J., Fernández‐Suárez, M. E., Falah, M. M., Smith, D. A., Smith, C., Kaya, E., Palmer, A. M., Fog, C. K., Kirkegaard, T., & Platt, F. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104374 · Cited by 14

Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders

Li, W., & Cologna, S. M. (2022) · Molecular Omics · doi:10.1039/d2mo00004k · Cited by 13

Mechanistic insights into arimoclomol mediated effects on lysosomal function in Niemann-pick type C disease

Shammas, H., Fog, C. K., Klein, P., Koustrup, A., Pedersen, M. T., Bie, A. S., Mickle, T. C., Petersen, N. H. T., Jensen, T. K., & Guenther, S. M. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109103 · Cited by 12

Tolerance of chronic HDACi treatment for neurological, visceral and lung Niemann-Pick Type C disease in mice

Alam†, M. S., Cooper, B. R., Farris, J. D., & Haldar, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-22162-7 · Cited by 11

Transcript, protein, metabolite and cellular studies in skin fibroblasts demonstrate variable pathogenic impacts of NPC1 mutations

Mušálková, D., Majer, F., Kuchař, L., Lukšan, O., Asfaw, B., Vlášková, H., Štorkánová, G., Řeboun, M., Poupětová, H., Jahnová, H., et al. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01360-5 · Cited by 10

Assessment of FDA-Approved Drugs as a Therapeutic Approach for Niemann-Pick Disease Type C1 Using Patient-Specific iPSC-Based Model Systems

Völkner, C., Pantoom, S., Liedtke, M., Lukáš, J., Hermann, A., & Frech, M. J. (2022) · Cells · doi:10.3390/cells11030319 · Cited by 10

HSP70 reverses lysosomal pathology

Crunkhorn, S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.220 · Cited by 2

Modulating the heat-shock response : a potential therapy for lysosomal storage disorders

Gray, J. A. R. (2014) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-gp70p2zao

Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology

Kirkegaard, T., Roth, A. G., Petersen, N. H. T., Mahalka, A. K., Olsen, O. D., Moilanen, I., Zylicz, A., Knudsen, J., Sandhoff, K., Arenz, C., et al. (2010) · Nature · doi:10.1038/nature08710 · Cited by 519

Heat shock protein 70 (Hsp70)

(2010) · Science-Business eXchange · doi:10.1038/scibx.2010.193

Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases

Hemsley, K. M., & Hopwood, J. J. (2009) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp47118 · Cited by 29